IO Biotech Announces First Patient Dosed in Investigator-Initiated Phase 1 Trial at University of California Davis Comprehensive Cancer Center
July 28 2023 - 8:05AM
IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical
company developing novel, immune-modulating cancer vaccines based
on its T-win® technology platform, announced today that the
University of California Davis Comprehensive Cancer Center has
dosed the first patient in its investigator-initiated trial which
aims to evaluate IO102-IO103, the company’s investigational
immune-modulating cancer vaccine, in combination with pembrolizumab
in patients with BCG-unresponsive or intolerant, non-muscle
invasive bladder cancer (NMIBC). This is one of five
investigator-initiated trials IO Biotech is supporting to evaluate
IO102-IO103 in combination with different checkpoint
inhibitor-based regimens across a variety of cancer types.
Mamta Parikh, MD, MS, Associate Professor at the
UC Davis School of Medicine, Division of Hematology Oncology, and
principal investigator for the UC Davis Comprehensive Cancer Center
Phase I clinical trial, commented, “I look forward to working with
IO Biotech on this trial to further investigate the possible use of
IO102-IO103 in combination with pembrolizumab to treat patients
with non-muscle invasive bladder cancer. Bladder cancer is one of
the most common forms of cancer and there remains a critical unmet
need for these patients who may be averse to invasive bladder
removal surgery or unresponsive to currently available therapies
and we look forward to the results of this study.”
“We are pleased to be supporting this trial with
the University of California Davis Comprehensive Cancer Center,”
said Mai-Britt Zocca, PhD, President and CEO of IO Biotech. “In
previous trials, we have seen that combination therapies with our
lead product candidate, IO102-IO103, induce meaningful tumor
regression while still achieving manageable tolerability for
patients. We look forward to seeing the safety and efficacy results
of this trial to further support the development of IO102-IO103 as
the potential backbone of combination therapies for treating
multiple types of cancer.”
About IO102-IO103
IO102-IO103 is an investigational
immune-modulating cancer vaccine designed to target the
immunosuppressive mechanisms mediated by the proteins indoleamine
2,3-dioxygenase (IDO) and PD-L1. The company is currently
conducting a Phase 3 trial (IOB-013/KN-D18; NCT05155254) evaluating
IO102-IO103 in combination with pembrolizumab in first-line
advanced melanoma patients. The company is also conducting a Phase
2 basket trial (IOB-022/KN-D38; NCT05077709), a non-comparative,
open label trial to investigate the safety and efficacy of
IO102-IO103 in combination with pembrolizumab for the first-line
treatment of each of the following advanced cancers: non-small cell
lung cancer (NSCLC), squamous cell carcinoma of the head and neck
(SCCHN), and urothelial bladder cancer (UBC).
About IO Biotech
IO Biotech is a clinical-stage biopharmaceutical
company developing novel, immune-modulating cancer vaccines based
on its T-win® vaccine platform. The T-win platform is a novel
approach to cancer vaccines designed to activate T cells to target
the most important immunosuppressive cells in the tumor
microenvironment. IO Biotech is advancing in clinical studies its
lead cancer vaccine candidate, IO102-IO103, targeting IDO and
PD-L1, and through preclinical development its other pipeline
candidates. IO Biotech is headquartered in Copenhagen, Denmark and
has US headquarters in New York, New York.
For further information, please visit
www.iobiotech.com.
Forward-Looking Statement
This press release contains forward-looking
statements within the meaning of Section 27A of the Securities Act
of 1933, as amended, and Section 21E of the Securities Exchange Act
of 1934, as amended. Forward-looking statements, including
regarding the timing of the interim analysis of our Phase 3 trial,
current or future clinical trials, their progress, enrollment or
results, or the company’s financial position or cash runway, are
based on IO Biotech’s current assumptions and expectations of
future events and trends, which affect or may affect its business,
strategy, operations or financial performance, and actual results
and other events may differ materially from those expressed or
implied in such statements due to numerous risks and uncertainties.
Forward-looking statements are inherently subject to risks and
uncertainties, some of which cannot be predicted or quantified.
Because forward-looking statements are inherently subject to risks
and uncertainties, you should not rely on these forward-looking
statements as predictions of future events. These forward-looking
statements speak only as of the date hereof and should not be
unduly relied upon. Except to the extent required by law, IO
Biotech undertakes no obligation to update these statements,
whether as a result of any new information, future developments or
otherwise.
Company Contact:Maryann Cimino, Director of
Investor RelationsIO Biotech,
Inc.617-710-7305mci@iobiotech.com
IO Biotech (NASDAQ:IOBT)
Historical Stock Chart
From Apr 2024 to May 2024
IO Biotech (NASDAQ:IOBT)
Historical Stock Chart
From May 2023 to May 2024